Arris to Collaborate With SmithKline Beecham to Apply Delta Technology to Infectious Disease Targets.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--June 27, 1996-- Arris Pharmaceutical Corporation (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARRS ARRS American Roentgen Ray Society. ) announced today that it has agreed to collaborate with SmithKline Beecham (NYSE NYSE See: New York Stock Exchange : SBE SBE - Microsoft Office Small Business Edition ) to explore the application of Arris' proprietary Delta technology to intracellular antiviral protease targets. The agreement incorporates an initial proof-of-concept phase followed by a research and development collaboration. While detailed financial terms were not disclosed, Arris indicated that the agreement includes a commitment fee, research and development support, milestones and royalties based on the overall success of the program. According to Daniel Petree, Arris' executive vice president of corporate development and chief financial officer, "This collaboration is important because it marks two `firsts' for Arris: our first research opportunity in the infectious disease category and our first expansion of the Delta technology to intracellular as opposed to extracellular serine and cysteine cysteine (sĭs`tēn), organic compound, one of the 20 amino acids commonly found in animal proteins. Only the l-stereoisomer participates in the biosynthesis of mammalian protein. proteases. Because intracellular targets are known to play significant roles in pathogen invasion and survival, we believe that protease inhibitors may provide new therapeutic alternatives to current treatments. "Our approach to this collaboration also represents a new strategic initiative for Arris. We are supporting an effort to apply the Delta technology to infectious disease targets that are of strategic interest to SmithKline. This type of arrangement provides Arris an opportunity to take advantage of SmithKline's experience in medicinal chemistry, molecular biology, biochemistry and structural analysis of these targets," Petree added. Arris Pharmaceutical uses an integrated drug discovery approach combining structure-based drug design, combinatorial chemistry and its proprietary Delta technology to discover and develop small molecule therapeutics for existing markets where available therapies have significant limitations. Arris' product development programs include: protease-based discovery programs targeting the inhibition of enzymes implicated in inflammatory and certain other diseases such as asthma, blood clotting disorders, arthritis, osteoporosis, cancer and various infectious disease; and receptor-based discovery programs, including those designed to discover small molecule drugs that mimic therapeutically important proteins, such as EPO EPO see erythropoietin. EPO Erythropoietin, see there , hGH, G-CSF G-CSF granulocyte colony-stimulating factor. G-CSF granulocyte-colony stimulating factor. G-CSF Granulocyte colony-stimulating factor Molecular therapeutics A biological response modifier, the recombinant DNA form of and TPO, and research programs to develop drugs that modulate the activity of receptors involved in diseases such as cancer and diabetes. CONTACT: Arris Pharmaceutical Daniel H. Petree or Shari Annes, 415/829-1000 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion